Mouret-Reynier MA - Search Results

1

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Bachelot T, Cottu P, Chabaud S, Dalenc F, Allouache D, Delaloge S, Jacquin JP, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Del Piano F, Debled M, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Barthelemy P, Kaluzinski L, Mailliez A, Legouffe E, Sephton M, Bliss J, Canon JL, Penault-Llorca F, Lemonnier J, Cameron D, Andre F. Bachelot T, et al. J Clin Oncol. 2022 Nov 10;40(32):3699-3708. doi: 10.1200/JCO.21.02179. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605174 Clinical Trial.

2

Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy.

Amat S, Penault-Llorca F, Cure H, Le Bouedëc G, Achard JL, Van Praagh I, Feillel V, Mouret-Reynier MA, Dauplat J, Chollet P. Amat S, et al. Int J Oncol. 2002 Apr;20(4):791-6. Int J Oncol. 2002. PMID: 11894126 Clinical Trial.

3

Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy.

Curé H, Amat S, Penault-Llorca F, le Bouëdec G, Ferrière JP, Mouret-Reynier MA, Kwiatkowski F, Feillel V, Dauplat J, Chollet P. Curé H, et al. Breast Cancer Res Treat. 2002 Nov;76(1):37-45. doi: 10.1023/a:1020274709327. Breast Cancer Res Treat. 2002. PMID: 12408374

4

Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin.

Mouret-Reynier MA, Abrial CJ, Ferrière JP, Amat S, Curé HD, Kwiatkowski FG, Feillel VA, Lebouëdec G, Penault-Llorca FM, Chollet PJ. Mouret-Reynier MA, et al. Clin Breast Cancer. 2004 Oct;5(4):303-7. doi: 10.3816/cbc.2004.n.035. Clin Breast Cancer. 2004. PMID: 15507178 Clinical Trial.

5

Does survival increase in metastatic breast cancer with recently available anticancer drugs?

Abrial C, Leheurteur M, Cabrespine A, Mouret-Reynier MA, Durando X, Ferriere JP, Kwiatkowski F, Penault-Llorca F, Cure H, Chollet P. Abrial C, et al. Oncol Res. 2006;15(9):431-9. doi: 10.3727/096504005776568264. Oncol Res. 2006. PMID: 16555549

6

Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.

Amat S, Mouret-Reynier MA, Penault-Llorca F, Leheurteur M, Delva R, Coudert B, Leduc B, Dauplat J, Curé H, Chollet P. Amat S, et al. Clin Breast Cancer. 2006 Aug;7(3):262-9. doi: 10.3816/CBC.2006.n.039. Clin Breast Cancer. 2006. PMID: 16942644 Clinical Trial.

7

Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer.

Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Leheurteur M, Gimbergues P, Tortochaux J, Curé H, Chollet P. Penault-Llorca F, et al. Oncologist. 2007 Apr;12(4):390-6. doi: 10.1634/theoncologist.12-4-390. Oncologist. 2007. PMID: 17470681 Free article.

8

Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy.

Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P, Curé H, Chollet P. Tacca O, et al. Oncologist. 2007 Jun;12(6):636-43. doi: 10.1634/theoncologist.12-6-636. Oncologist. 2007. PMID: 17602055 Free article.

9

Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.

Gimbergues P, Abrial C, Durando X, Le Bouedec G, Cachin F, Penault-Llorca F, Mouret-Reynier MA, Kwiatkowski F, Maublant J, Tchirkov A, Dauplat J. Gimbergues P, et al. Ann Surg Oncol. 2008 May;15(5):1316-21. doi: 10.1245/s10434-007-9759-z. Epub 2008 Mar 1. Ann Surg Oncol. 2008. PMID: 18311507

10

A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN).

Chollet P, Abrial C, Durando X, Thivat E, Tacca O, Mouret-Reynier MA, Leheurteur M, Kwiatkowski F, Dauplat J, Penault-Llorca F. Chollet P, et al. Cancer J. 2008 Mar-Apr;14(2):128-32. doi: 10.1097/PPO.0b013e31816bdea2. Cancer J. 2008. PMID: 18391619

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

147 results

Search Page